Evidence map›Paper›PMID 42577072›Full record

ArticleJMA journal2026

Differences in Rheological Properties between Brand and Generic Metronidazole Gels and Their Potential Impact on Malodor Management in Cancer Survivors.

Atsushi Ishimura, Shiori Obuchi, Naohiro Yabuki, Motoki Inoue

Abstract read
In one paragraph

Article in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Atsushi IshimuraLaboratory of Clinical Pharmacy Assessment, Hoshi University, Shinagawa-Ku, Tokyo, Japan.
Shiori ObuchiLaboratory of Clinical Pharmacy Assessment, Hoshi University, Shinagawa-Ku, Tokyo, Japan.
Naohiro YabukiPharmaceutical Department of Sainokuni Higashi Omiya Medical Center, Saitama-shi, Saitama, Japan.
Motoki InoueDepartment of Physical Chemistry, Hoshi University, Shinagawa-Ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Malignant fungating wounds often produce strong malodors caused by anaerobic bacterial proliferation, which severely impairs the quality of life of cancer survivors and their caregivers. Topical metronidazole is widely used as a first-line option for odor control; however, differences in the rheological (Q3) attributes between brand-name and generic gel formulations may influence spreadability, retention on the wound surface, and overall usability. The study aimed to compare the rheological properties of brand and generic metronidazole gels marketed in Japan and to discuss their potential impact on malodor management. Methods: Brand (Rozex Results: Both formulations exhibited shear-thinning behavior; however, the brand gel showed consistently higher viscosity across all shear rates, with a pronounced difference at low shear rates relevant to wound application. The brand product demonstrated a narrower thixotropic hysteresis loop (approximately 26-fold difference), indicating faster structural recovery. Viscoelastic measurements showed higher G' values and a wider LVR for the brand gel, suggesting a stronger gel network. Frequency sweep analysis revealed strong-gel behavior for the brand formulation, whereas the generic gel exhibited weak-gel characteristics. These rheological differences corresponded to differences in base polymers-carboxyvinyl polymer in the brand gel and hydrophobically modified hydroxypropyl methylcellulose in the generic. Conclusions: Although containing identical active ingredients, the two formulations exhibit distinct rheological profiles that may affect clinical handling and usability in malodor management. Q3 attributes should be considered when selecting topical products for cancer survivors with fungating wounds.

Indexed as

gel network structuremetronidazole gelpolymer excipientsrheology / Q3 characterizationtopical semisolid formulation

Identifiers

PMID42577072
PMCPMC13453665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.